Company registration number 07194096 (England and Wales)
BIOMETRIC TECHNOLOGIES LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
PAGES FOR FILING WITH REGISTRAR
BIOMETRIC TECHNOLOGIES LTD
CONTENTS
Page
Accountants' report
1
Balance sheet
2
Notes to the financial statements
3 - 6
BIOMETRIC TECHNOLOGIES LTD
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF BIOMETRIC TECHNOLOGIES LTD FOR THE YEAR ENDED 30 JUNE 2024
- 1 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Biometric Technologies Ltd for the year ended 30 June 2024 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the board of directors of Biometric Technologies Ltd, as a body, in accordance with the terms of our engagement letter dated 12 January 2022. Our work has been undertaken solely to prepare for your approval the financial statements of Biometric Technologies Ltd and state those matters that we have agreed to state to the board of directors of Biometric Technologies Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Biometric Technologies Ltd and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Biometric Technologies Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Biometric Technologies Ltd. You consider that Biometric Technologies Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Biometric Technologies Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Carpenter Box
27 March 2025
Chartered Accountants
5 Peveril Court
6-8 London Road
Crawley
West Sussex
RH10 8JE
BIOMETRIC TECHNOLOGIES LTD
BALANCE SHEET
AS AT
30 JUNE 2024
30 June 2024
- 2 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
2,118
1,190
Current assets
Debtors
4
78,914
89,981
Cash at bank and in hand
2,773
84,170
81,687
174,151
Creditors: amounts falling due within one year
5
(564,607)
(571,537)
Net current liabilities
(482,920)
(397,386)
Total assets less current liabilities
(480,802)
(396,196)
Creditors: amounts falling due after more than one year
6
(2,105,345)
(2,061,307)
Net liabilities
(2,586,147)
(2,457,503)
Capital and reserves
Called up share capital
7
715,275
715,275
Profit and loss reserves
(3,301,422)
(3,172,778)
Total equity
(2,586,147)
(2,457,503)

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 27 March 2025
Mr S M Napoli
Director
Company registration number 07194096 (England and Wales)
BIOMETRIC TECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
- 3 -
1
Accounting policies
Company information

Biometric Technologies Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 128 City Road, London, EC1V 2NX.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the year end the company has net current liabilities and net liabilities. Although the company shows net liabilities, it has the support of the company director's related company. The director has a reasonable expectation that the company will continue in operational existence for the foreseeable future and consequently these financial statements are prepared on the going concern basis. No adjustment has been made to the carrying values of assets and liabilities should that basis not be appropriate.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
33.33% per annum on a straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

BIOMETRIC TECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
1
Accounting policies
(Continued)
- 4 -
1.5
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

BIOMETRIC TECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
1
Accounting policies
(Continued)
- 5 -
1.10
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.11
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons employed by the company during the year was 1 (2023 - 2).

3
Tangible fixed assets
Plant and equipment
£
Cost
At 1 July 2023
68,407
Additions
1,308
At 30 June 2024
69,715
Depreciation and impairment
At 1 July 2023
67,217
Depreciation charged in the year
380
At 30 June 2024
67,597
Carrying amount
At 30 June 2024
2,118
At 30 June 2023
1,190
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
69,039
80,106
Other debtors
9,875
9,875
78,914
89,981
BIOMETRIC TECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
- 6 -
5
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
380,710
346,567
Taxation and social security
179,444
220,422
Other creditors
4,453
4,548
564,607
571,537
6
Creditors: amounts falling due after more than one year
2024
2023
£
£
Other creditors
2,105,345
2,061,307
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
10
10
10
10
Ordinary K shares of £1 each
715,265
715,265
715,265
715,265
715,275
715,275
715,275
715,275
8
Financial commitments, guarantees and contingent liabilities

As of 30 June 2024, the company has a financial commitment of £12,740 (2023 - £10,800)

2024-06-302023-07-01false27 March 2025CCH SoftwareCCH Accounts Production 2024.200No description of principal activityMr S M Napolifalsefalse071940962023-07-012024-06-30071940962024-06-30071940962023-06-3007194096core:PlantMachinery2024-06-3007194096core:PlantMachinery2023-06-3007194096core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3007194096core:CurrentFinancialInstrumentscore:WithinOneYear2023-06-3007194096core:Non-currentFinancialInstrumentscore:AfterOneYear2024-06-3007194096core:Non-currentFinancialInstrumentscore:AfterOneYear2023-06-3007194096core:CurrentFinancialInstruments2024-06-3007194096core:CurrentFinancialInstruments2023-06-3007194096core:ShareCapital2024-06-3007194096core:ShareCapital2023-06-3007194096core:RetainedEarningsAccumulatedLosses2024-06-3007194096core:RetainedEarningsAccumulatedLosses2023-06-3007194096core:ShareCapitalOrdinaryShares2024-06-3007194096core:ShareCapitalOrdinaryShares2023-06-3007194096bus:Director12023-07-012024-06-3007194096core:PlantMachinery2023-07-012024-06-30071940962022-07-012023-06-3007194096core:PlantMachinery2023-06-3007194096core:WithinOneYear2024-06-3007194096core:WithinOneYear2023-06-3007194096core:Non-currentFinancialInstruments2024-06-3007194096core:Non-currentFinancialInstruments2023-06-3007194096bus:PrivateLimitedCompanyLtd2023-07-012024-06-3007194096bus:SmallCompaniesRegimeForAccounts2023-07-012024-06-3007194096bus:FRS1022023-07-012024-06-3007194096bus:AuditExemptWithAccountantsReport2023-07-012024-06-3007194096bus:FullAccounts2023-07-012024-06-30xbrli:purexbrli:sharesiso4217:GBP